Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.

immatics biotechnologies GmbH, together with its collaborators Cancer Research UK and Cancer Research Technology has announced that they have entered a license agreement in which immatics will continue to develop its cancer vaccine IMA950 for glioblastoma, the most common and lethal adult brain tumour.

The decision is based on positive results from a phase 1 trial that was conducted under the Clinical Development Partnerships (CDP) joint initiative of Cancer Research UK’s Drug Development Office (DDO) and Cancer Research Technology (CRT) as part of the charity’s role in assessing new treatments of potential benefit to cancer patients.

IMA950 is a vaccine that uses 11 different HLA-restricted tumour-associated peptides (TUMAPs). The TUMAPs, identified by immatics using its proprietary drug discovery platform XPRESIDENT®, are known to be over-expressed on the surface of glioblastoma tumours. They trigger the patient’s immune system to recognize and kill tumour cells while leaving healthy cells unharmed.

The IMA950 trial met the agreed primary endpoints of safety and immunogenicity in a phase 1 multicentre trial which was undertaken at seven Experimental Cancer Medicine Centres across the UK, led by the Beatson West of Scotland Cancer Centre in Glasgow. 45 patients with newly diagnosed glioblastoma were treated with IMA950 in addition to standard of care, surgery and concomitant or adjuvant chemotherapy with temozolomide. Results showed that 90 per cent of patients responded to the vaccine, in comparison to the pre-defined goal of 60 per cent, exceeding expectations.

IMA950 is the first therapeutic vaccine developed under the CDP scheme. Under the scheme, companies retain rights to their drugs while allowing Cancer Research UK’s DDO to undertake early clinical development work to assess the treatment’s benefit to cancer patients.

Nine projects have been taken on under the CDP initiative with IMA950 being the first to complete a clinical trial and be taken forward by the company. immatics has paid CRT an undisclosed licensing fee for exclusive rights to the phase 1 clinical trial data and, provided IMA950 is successfully developed and commercialized, will pay further development milestones and downstream royalties.

Professor Roy Rampling, chief investigator for the study and Honorary Senior Research Fellow at the Beatson West of Scotland Cancer Centre, said: “Brain tumours are a particularly difficult type of cancer to treat with conventional methods, but they have recently been accepted as a possible target for immunotherapy - increasingly recognized as a potentially important approach to treating cancer.

“In our study we investigated whether patients newly diagnosed with the most common and aggressive type of malignant brain tumour called glioblastoma could mount an appropriate immune response when given IMA950 and if the vaccine was safe. IMA950 was very simple to administer and was very well tolerated. Importantly, we were very pleased to see that nearly all patients mounted an immune response that could be detected in the blood, which is the first step in establishing clinical activity before determining patient benefit in subsequent studies.”

Paul Higham, CEO of immatics, said: “I am delighted that we are in a position to take the development of IMA950 forward for the treatment of patients with glioblastoma. This is our third cancer vaccine to have shown promising results. There is clearly a high need for new therapies for glioblastoma, which is a very hard-to-treat cancer, with very poor survival rates. The DDO has been an excellent partner and we are very grateful for the work they have done in further characterizing the positive attributes of IMA950.”

Dr Nigel Blackburn, Cancer Research UK’s director of the DDO, said: “We’re extremely pleased that our collaboration with immatics has yielded positive phase 1 data with IMA950 and that through our Clinical Development Partnerships initiative we have been able to ensure it has the potential to reach patients sooner. Better treatment options for glioblastoma are badly needed and we hope that the potential of this novel approach will be confirmed in future clinical studies.

“Cancer Research UK is committed to playing a key role in the development of improved cancer therapies and we see collaborations with a broad range of partners, such as immatics, as critical to achieving this very important goal.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
immatics Closes €34 Million Financing
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.
Tuesday, October 15, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!